Chemical-structure (Atorvastatin Calcium 80mg Tablet 1)
Atorvastatin Calcium
Product Images NDC 53217-319
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 53217-319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-01 (Atorvastatin Calcium 80mg Tablet 2)
Figure-02 (Atorvastatin Calcium 80mg Tablet 3)
This appears to be a graph displaying the cumulative hazard percentage for Atorvastatin over a period of four years. The graph shows that after four years, there is a hazard percentage of 15%. Additionally, there is a reference to a hazard ratio of 0.53 for Atorvastatin.*
Figure-03 (Atorvastatin Calcium 80mg Tablet 4)
This text is describing the results of a study involving two different doses of cholesterol-lowering medications (Horvastatin 10 mg and Sorvastatin 80 mg) and the percentage of subjects who experienced E vert (unclear what this is). The study found that Horvastatin 10 mg was associated with a lower risk of a major cardiovascular endpoint compared to Sorvastatin 80 mg. The text also provides a Hazard Ratio (HR) with its confidence interval and p-value. Finally, there is a graph titled "Time to First Major Cardiovascular Endpoint" with four time points.*
Atorvastatin Calcium 80mg Tablet (Atorvastatin Calcium 80mg Tablet 5)
ATORVASTATIN CALCIUM is a medication in the form of pills with a strength of 10mg. It comes in packaging of 8 pills with an identification code of 1001871798. The rest of the text is not-readable/ not-available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
